Analyst Says Obagi (OMPI) Could Soon See Offers from 'Multiple Suitors'

Investors are dipping a toe into shares of Obagi Medical Products (Nasdaq: OMPI) Monday morning as Cantor Fitzgerald's Irina Rivkind said the company could be attractive to "multiple suitors." The stock is up about 2 percent at last check.

The analyst named Valeant (NYSE: VRX), Medicis (NYSE: MRX) and Allergan (NYSE: AGN) as potential interested companies, and also said a pure-play cosmetics company could also get involved.

Rivkind called Obagi attractive given its "brand recognition" and reputation for efficacy. The analyst also pointed to the company's pristine balance sheet and "healthy" growth.

Track all the market-moving analyst calls on shares of Obagi with our Analyst Ratings page.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor
• Canaccord Downgrades Northern Star Resources (NST:AU) (NESRF) to Hold